• Explore /
  • Poster
  • / Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK.

Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK.

Abstract Video & Slides Poster

Authors

null

Stephen J. Freedland

Division of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA and Durham VA Medical Center, Durham, NC

Stephen J. Freedland , Paul R. Sieber , Martin Gleave , Ugo De Giorgi , Bryan Allyn Mehlhaff , Daniel Costin Danila , Curtis Dunshee , Costas D. Lallas , Marc Pliskin , Yiyun Tang , Gabriel P. Haas , Matt Rosales , Jamal Christo Christo Tarazi , Fabian Zohren , David Russell , Neal D. Shore

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02319837

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 156)

DOI

10.1200/JCO.2024.42.4_suppl.156

Abstract #

156

Poster Bd #

G6

Abstract Disclosures

Similar Posters

First Author: Wesley Robert Armstrong

First Author: Fred Saad

First Author: A. Oliver Sartor

First Author: Robert B. Montgomery